eGenesis vs Figma
Side-by-side comparison of AI visibility scores, market position, and capabilities
FDA-cleared IND for CRISPR-edited pig kidney (ESKD Phase 1/2/3). First patient dialysis-free at 7+ months post-transplant. 69-gene-edited pig — most complex CRISPR ever.
About
eGenesis is developing gene-edited pig organs for human transplantation — xenotransplantation — using a 69-gene CRISPR editing protocol that simultaneously knocks out pig genes that trigger human rejection, adds human immune tolerance genes, and eliminates porcine endogenous retroviruses. The company received FDA clearance for its IND for EIGEN-2784 (a gene-edited pig kidney) for end-stage kidney disease, and its first transplant patient remained dialysis-free at more than 7 months post-transplant — the longest reported survival for a xenotransplantation recipient.
Dominant browser-based collaborative UI design platform at ~$600M ARR and $12.5B valuation; Adobe's $20B acquisition blocked by regulators in 2023, Figma remains independent competing with Sketch and Adobe.
About
Figma is a San Francisco-based collaborative web-based product design platform that has become the dominant tool for UI/UX designers and product teams — enabling real-time multi-user collaboration on interface design, prototyping, and design system management directly in the browser without installing desktop software. Founded in 2012 by Dylan Field and Evan Wallace and backed by Sequoia, Greylock, and Andreessen Horowitz with over $330 million raised, Figma generated approximately $600 million in ARR in 2023, serving 4 million+ designers and product teams at companies including Microsoft, Airbnb, Twitter, and Uber. Adobe announced a $20 billion acquisition offer in 2022, which was blocked by regulators in 2023 — Figma remains independent.
AI Visibility Head-to-Head
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.